Provexis Regulatory News (PXS)

9 Dec 2005 07:00

Provexis PLC09 December 2005 9 December 2005 PROVEXIS PLC ("Provexis" or the "Company") Appointment of Finance Director Designate and Company Secretary Designate Provexis, the nutraceutical company that develops scientifically-provenfunctional and medical foods, announces the appointment of Stewart WilliamSlade, 56, as Finance Director designate and Company Secretary designate, withimmediate effect. Stewart succeeds Doug Gardner, who will step down from hisrole as interim Director of Finance, a non-Board position, on 14 December.Stewart will formally assume his position as Finance Director and CompanySecretary and join the Board of Provexis following the Company's Board Meetingon 10th January 2006. Stewart joins Provexis from Senetek PLC ("Senetek"), a life sciences company,headquartered in the U.S, engaged in the development and marketing ofproprietary pharmaceutical and cosmeceutical products that fulfil unmet consumerneeds related to aging. At Senetek, Stewart was Chief Financial Officer andCompany Secretary from 1998 until 2003 when he was appointed Vice President ofEuropean Operations, whilst continuing to act as Company Secretary. Stewart, who began his career as a research and development biochemist with theSmith Kline Corporation in 1971, qualified as a chartered accountant at Coopers& Lybrand, London in 1978. He joined Colgate Palmolive UK in 1980 as aninternational accountant and proceeded to work with Colgate Palmolive's Indianand then Caribbean operations as financial controller. In 1986 he joined DuBoisChemicals Ltd, the speciality chemicals and industrial cleaning systemssubsidiary of Chemed Corporation, as Financial Director and Company Secretary.Following the acquisition of DuBois by Diversey Limited (now Johnson Diversey)in 1991, Stewart was appointed Financial Director of the European Operationsgroup at Diversey. Commenting on the appointment, Dr Stephen Franklin, Chief Executive of Provexis,said: "We are delighted to welcome Stewart to the company. He has excellentcredentials and a wealth of experience having worked with major chemical andhealthcare companies. We look forward to benefiting from the valuablecontribution that his international, operational and financial expertise canbring to the company." There are no further disclosures to be made in accordance with Rule 17 andschedule 2 (g) of the AIM Rules. For further information please contact: Provexis plcDr Stephen Franklin 0208 392 6631 Bell Pottinger Corporate & FinancialAnn-Marie Wilkinson/Emma Kent 020 7861 3232 This information is provided by RNS The company news service from the London Stock Exchange